Background
Phase III, open-label, randomized trial. 587 patients with RRMM who had received 1–3 prior lines of therapy, including at least one proteasome inhibitor and one immunomodulatory agent. Teclistamab is a bispecific BCMA×CD3 T-cell engager; daratumumab targets CD38. Comparator arms were investigator-selected: DPd (daratumumab + pomalidomide + dex) or DVd (daratumumab + bortezomib + dex). NCT05083169.
Interventions and follow up
Arm A: Teclistamab (subcutaneous, step-up dosing) + daratumumab (IV/SC)
Arm B: DPd (daratumumab + pomalidomide 4 mg D1–21 + dexamethasone) or DVd (daratumumab + bortezomib + dexamethasone) per investigator's choice
Primary endpoint: IRC-assessed progression-free survival (PFS)
mFollow up: 34.5 months
Arm B: DPd (daratumumab + pomalidomide 4 mg D1–21 + dexamethasone) or DVd (daratumumab + bortezomib + dexamethasone) per investigator's choice
Primary endpoint: IRC-assessed progression-free survival (PFS)
mFollow up: 34.5 months
Results
PFS (36-month rate): 83.4% vs 29.7%, HR 0.17, 95% CI 0.12–0.23, P<.001
CR or better: 81.8% vs 32.1%, P<.001
ORR: 89.0% vs 75.3%, P<.001
MRD negativity (10−5): 58.4% vs 17.1%, P<.001
CR or better: 81.8% vs 32.1%, P<.001
ORR: 89.0% vs 75.3%, P<.001
MRD negativity (10−5): 58.4% vs 17.1%, P<.001
Adverse events
Overall toxicity: Serious adverse events 70.7% vs 62.4%; adverse-event-related deaths 7.1% vs 5.9%
Immune/infectious: CRS occurred with teclistamab step-up dosing (grade ≥3 CRS uncommon); infections, including opportunistic infections, were the most clinically relevant concern in the teclistamab arm, consistent with T-cell engager class effects
Immune/infectious: CRS occurred with teclistamab step-up dosing (grade ≥3 CRS uncommon); infections, including opportunistic infections, were the most clinically relevant concern in the teclistamab arm, consistent with T-cell engager class effects
Conclusions
Teclistamab + daratumumab demonstrated dramatically superior PFS, response depth, and MRD negativity rates compared with standard daratumumab-based doublet/triplet regimens in 1–3 prior lines RRMM, establishing a new standard-of-care benchmark in early relapse.
Key Limitations
Open-label design. Comparator arms were heterogeneous (DPd vs DVd per investigator choice), complicating cross-arm interpretation. The 1–3 prior lines population overlaps with first-relapse disease where triplet approaches (carfilzomib-based, isatuximab-based) are also highly active — comparative data are lacking. Treatment-related mortality (7.1%) reflects the immunosuppression risk of bispecifics. Long-term immunosuppression, hypogammaglobulinemia, and infection management remain challenges.
Clinical Context
This trial positions dual BCMA/CD38 targeting as a transformative approach in early-relapse MM. Teclistamab monotherapy was already approved for heavily pretreated MM; combining it with daratumumab in earlier lines dramatically deepens responses. BCMA-directed bispecific combinations are expected to reshape relapsed/refractory MM algorithms, potentially competing with CAR-T approaches (CARTITUDE-4 showed cilta-cel superiority in 1–3 prior lines).